H
Hans K. Müller-Hermelink
Researcher at University of Würzburg
Publications - 32
Citations - 5992
Hans K. Müller-Hermelink is an academic researcher from University of Würzburg. The author has contributed to research in topics: Lymphoma & Mantle cell lymphoma. The author has an hindex of 21, co-authored 32 publications receiving 5518 citations. Previous affiliations of Hans K. Müller-Hermelink include University of Ulm & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis,Vu N. Ngo,Georg Lenz,Pavel Tolar,Ryan M. Young,Paul B. Romesser,Holger Kohlhammer,Laurence Lamy,Hong Zhao,Yandan Yang,Weihong Xu,Arthur L. Shaffer,George E. Wright,Wenming Xiao,John Powell,Jian Kang Jiang,Craig J. Thomas,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Nathalie A. Johnson,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Wyndham H. Wilson,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Susan K. Pierce,Louis M. Staudt +36 more
TL;DR: Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Journal ArticleDOI
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo,Vu N. Ngo,Ryan M. Young,Roland Schmitz,Sameer Jhavar,Wenming Xiao,Kian-Huat Lim,Holger Kohlhammer,Weihong Xu,Yandan Yang,Hong Zhao,Arthur L. Shaffer,Paul B. Romesser,George E. Wright,John Powell,Andreas Rosenwald,Hans K. Müller-Hermelink,German Ott,Randy D. Gascoyne,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Denny D. Weisenburger,Wing C. Chan,Louis M. Staudt +31 more
TL;DR: The dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, is described and the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MyD88 mutations are supported.
Journal ArticleDOI
Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Georg Lenz,R. Eric Davis,Vu N. Ngo,Lloyd T. Lam,Thaddeus C. George,George E. Wright,Sandeep S. Dave,Hong Zhao,Weihong Xu,Andreas Rosenwald,German Ott,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Wing C. Chan,Louis M. Staudt +22 more
TL;DR: It is demonstrated that CARD11 is a bona fide oncogenein DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway forDLBCL therapy.
Journal Article
The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type
German Ott,Tiemo Katzenberger,Axel Greiner,Jörg Kalla,Andreas Rosenwald,Ute Heinrich,M. Michaela Ott,Hans K. Müller-Hermelink +7 more
TL;DR: Analyzing the cytogenetics of 44 MALT lymphomas arising in the stomach, parotid gland, thyroid gland, lung, breast, and conjunctiva finds clonal chromosome aberrations have been detected in 13 of 20 (65%) low-grade and 20 of 24 (83%) high-grade tumors.
Journal ArticleDOI
Cooperative Epigenetic Modulation by Cancer Amplicon Genes
Lixin Rui,N. C. Tolga Emre,Michael J. Kruhlak,Hye Jung Chung,Christian Steidl,Graham W. Slack,George E. Wright,Georg Lenz,Vu N. Ngo,Arthur L. Shaffer,Weihong Xu,Hong Zhao,Yandan Yang,Laurence Lamy,R. Eric Davis,Wenming Xiao,John Powell,David G. Maloney,Craig J. Thomas,Peter Möller,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Kerry J. Savage,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Erlend B. Smeland,Dennis D. Weisenburger,Wing C. Chan,Randy D. Gascoyne,David Levens,Louis M. Staudt +35 more
TL;DR: JAK2 and JMJD2C cooperatively remodel the PMBL and HL epigenome, offering a mechanistic rationale for the development of JAK2-mediated histone phosphorylation and JM JD2C inhibitors in these diseases.